Odonate Therapeutics Revenue and Competitors

Claim your profile

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Odonate Therapeutics's estimated annual revenue is currently $9.3M per year.(i)
  • Odonate Therapeutics's estimated revenue per employee is $202,174
  • Odonate Therapeutics's current valuation is $43.1M. (January 2022)

Employee Data

  • Odonate Therapeutics has 46 Employees.(i)
  • Odonate Therapeutics grew their employee count by -78% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.7M619%$53MN/A
#2
$34.3M17717%$110MN/A
#3
$0.4M2735%$236.7MN/A
#4
$34.5M178-5%$160MN/A
#5
$3.7M2420%N/AN/A
#6
$147.3M3212%$192.5MN/A
#7
$17.5M113-3%$24.1MN/A
#8
$2.7M4379%N/AN/A
#9
$34.1M220100%N/AN/A
#10
$47.1M304-3%N/AN/A

Odonate Therapeutics is dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Our initial focus is on the development of tesetaxel, an investigational, orally administered taxane. We are conducting our multinational, multicenter, randomized, Phase 3 study in locally advanced or metastatic breast cancer (MBC), known as CONTESSA. Our goal is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives.

keywords:N/A

N/A

Total Funding

46

Number of Employees

$9.3M

Revenue (est)

-78%

Employee Growth %

$43.1M

Valuation

N/A

Accelerator

Odonate Therapeutics News

2022-04-17 - 2022-04-19 | PINL:ODTC | Press Release | Odonate ...

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Odonate Therapeutics, Inc. ODTC | 12 hours ago. Wilmington, Delaware--(Newsfile Corp. - April 19,...

2021-03-22 - Odonate Therapeutics Announces Discontinuation of Development of Tesetaxel

NEW YORK--(BUSINESS WIRE)--Mar 22, 2021-- Following feedback from the U.S. Food and Drug Administration (FDA) in a pre-New Drug Application meeting, Odonate Therapeutics, Inc. (NASDAQ: ODT) has concluded that the clinical data package for tesetaxel is unlikely to support FDA approval. Therefore ...

2019-09-08 - Odonate Therapeutics, Inc. (ODT) Loses -5.39% Worth of ...

Shares of Odonate Therapeutics, Inc. (ODT) have been trending lower over the past five bars, revealing bearish momentum for the shares, ...

2019-09-07 - Odonate Therapeutics, Inc. (:ODT) Shares Dip Under Moving ...

Shares of Odonate Therapeutics, Inc. (:ODT) have been on a recent steady downtrend, causing some worry for shareholders. Investors may be ...

2019-09-06 - Carillon Tower Advisers Inc. Purchases Shares of 459968 ...

Carillon Tower Advisers Inc. purchased a new stake in shares of Odonate Therapeutics Inc (NASDAQ:ODT) during the 2nd quarter, according ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$4.4M462%N/A
#2
$9.2M460%N/A
#3
$8.6M46-4%$72M
#4
$15M4610%N/A
#5
$3.5M4612%N/A